Company: CERO
Filing Date: 2025-11-28
Form Type: DEF 14A
Source: 0001213900-25-115783
Chunk: 32

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-28
Form: DEF 14A
Chunk 32
---
, the Conversion Price shall automatically adjust to such New Issuance Price on the date of stockholder approval. As a result of Dilutive Issuances through the date hereof, on the date of the stockholder approval, the Conversion Price would be adjusted to $0.05. The issuance of Common Stock upon the conversion of the Series E Preferred Stock at such a reduced conversion or exercise price may result in certain investors in the October 2025 Private Placement (the “October 2025 Investors”) acquiring more than 20% of the amount of Common Stock issued and outstanding prior to the October 2025 Private Placement at a price below the Minimum Price. Accordingly, the Company needs stockholder approval of the issuance of shares of Common Stock upon any such reset of the conversion of the Series E Preferred Stock. On the Record Date, assuming the issuance of all shares of Common Stock upon conversion of all of the shares of the Series E Preferred Stock (including the 3,816 shares of Series E Preferred Stock issued and outstanding and the 5,934 shares of Series E Preferred Stock that may be issued in additional closings), the October 2025 Investors would own approximately 2.3 million shares of Common Stock, assuming conversion at the initial conversion price of $4.1625 per share. Such shares would constitute approximately 10.1% of the then -outstandingCommon Stock after the issuance of such shares. Potential Adjustments Because the conversion price of the Series E Preferred Stock may be adjusted, the number of shares that will actually be issued may be more or less than such number of shares. Such adjustments include (i) adjustments to the conversion price upon the occurrence of an Adjustment Date, (ii) the application of the Alternate Conversion procedures set forth in Section 4(e) of the COD, including the application of the “Alternate Conversion Price” in lieu of the conversion price and (iii) the adjustment of the conversion price upon certain issuances of securities below such conversion price after the receipt of the stockholder approval sought by this proposal, as well as the adjustment upon receipt of such stockholder approval for any such issuances below the conversion price that occurred prior to such stockholder approval. The Alternate Conversion procedures apply (i) at any time following the Stockholder Approval Date (as defined in the COD), at the option of the holder or (ii) at any time following the Stockholder Approval Date following the occurrence 17 or during the continuance of a Triggering Event (as defined in the COD) until